GLMD GLMD
Company Profile ↓Company Overview
GLMD (GLMD) is a publicly traded company listed on with a market capitalization of $3.82M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -64.42% |
| 6 Months: | -13.43% |
| 3 Months: | -1.69% |
| 1 Month: | +1.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)52.67 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 64.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 1.26M | 2.11M | 2.10M | 3.04M | 2.04M |
| Operating Income | - | -1.26M | -2.11M | -2.10M | -3.04M | -2.04M |
| EBITDA | - | -1.26M | -2.11M | -2.10M | -3.04M | -2.04M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -1.10M | -2.50M | -1.89M | -4.82M | -1.91M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -1.10M | -2.50M | -1.89M | -4.82M | -1.91M |
| Diluted EPS | - | -0.62 | -0.63 | -0.33 | - | -0.29 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 17.65M | 7.49M | 6.28M | 8.51M |
| Operating Income | -17.65M | -7.49M | -6.28M | -8.51M |
| EBITDA | -17.62M | -7.46M | -6.20M | -8.51M |
| Interest Expense | - | - | - | - |
| Pretax Income | -17.87M | -6.91M | -7.52M | -10.31M |
| Tax Provision | - | - | - | - |
| Net Income | -17.87M | -6.91M | -7.52M | -10.31M |
| Diluted EPS | -127.80 | -30.00 | -8.08 | -2.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 16.56M | 16.63M | 18.50M | 18.63M |
| Current Assets | - | 14.72M | 13.24M | 16.12M | 18.63M |
| Cash & Equivalents | - | 2.02M | 2.86M | 4.65M | 3.98M |
| Inventory | - | - | - | - | - |
| Receivables | - | 157.00K | 165.00K | 209.00K | 80.00K |
| Total Liabilities | - | 3.14M | 2.75M | 2.17M | 2.85M |
| Current Liabilities | - | 3.09M | 2.75M | 2.17M | 2.85M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | 229.00K | 215.00K | 41.00K | 0 | - |
| Total Equity | - | 13.42M | 13.88M | 16.33M | 15.78M |
| Shares Outstanding | - | 140.02K | 420.44K | 1.66M | 6.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -18.50M | -6.14M | -5.88M | -6.32M |
| Investing Cash Flow | - | 17.56M | 800.00K | -1.11M | -3.38M |
| Financing Cash Flow | - | 70.00K | 6.18M | 8.79M | 9.03M |
| Capital Expenditure | -11.00K | -4.00K | - | - | - |
| Free Cash Flow | - | -18.50M | -6.14M | -5.88M | -6.32M |
| Net Change in Cash | - | -868.00K | 848.00K | 1.79M | -664.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -133.1% | -49.8% | -46.0% | -65.3% |
| ROCE % | -131.1% | -54.0% | -38.5% | -53.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GLMD
Galmed Pharmaceuticals Stock Price Forecast. Should You Buy GLMD? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE9Mb3d0cDdUZWsxenJkV21VWWtsd015c3lORUlfaXNsVXZhV3c2dHRlX0VMcmtEMzBndnM4Q204LTJhOXctSnhMaQ?oc=5" target="_blank">Galmed Pharmaceuticals Stock Price Forecast. Should You Buy GLMD?</a>…
Galmed Pharmaceuticals (NASDAQ: GLMD) granted new deadline to meet $1 bid rule - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNeUxjRG12MzFxOG9EQmFRcGtrWWhTMFFXT0xYNHh2dzFaX2wzejNXZlFWMjV5YWVtaE1nbGlBZHViRDFkVTE5SWE3YThXT0RoQTg2eEhDaXRvTXk5Ni1iZDRONExENkN5ZGJmVEMyUlJubEhCNTdVc25YZ0JmV3U0ZUhxMFNCYlktdlJOUE…
GLMD Stock Shot Up 55% Today After Rising 27% In 5 Days – What’s The Latest On Its Parkinson’s Disease Therapy? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxQQV9TQVJzTTdrNzE0bXRZX3BSU01OV1MzM3ZZcEhUM1l6UlVacW93cURWemo5RnJRZFZtQUxkRTdvRE5LcnJYLU5GWnNjUHB5aE8zd2piNXBzSmNEUVlOSThONHBNaXltQ3lIanJRMTg5TERfVTBCbTNtNm5TSUItQ0pNNUswTUkxZGlFbU…
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation - Galmed Pharmaceuticals (NASDAQ:GLMD) - Benzinga
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPWW5YS2hTamtvaVpCUmwzd2FvTzlEeEM2OUpWSmZTMXRCZVRybmJ2OVlmdHRxR3pDQUZHQ2tUNHA2SGRHWjRSMnNneFRPR1F5MHB6NjhleVN3TXNzcHJGcHRXNDFPNWtQZm1FRFJZYmlOVTk2cllwZGZRa0Z0aU1JMXZMbFE0ek9CaWRjUH…
Galmed Pharmaceuticals Sets August 26, 2026 Annual Meeting to Approve Governance and Structural Changes - theglobeandmail.com
<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxPSTBjendTUUtaSHdyREJqd1lFcFk4NlJqM0tFb1hpdEh6eWp3Z1NIOHNrMGtIT3g1VFpVRjdOcVRjUVJrWHE0VHhsN2xlUUtyTjJrWndnR0lBbHlOaXRxRlJVY0NKMXc3V2hJcEZFWDl0U3JyTlZxODhTZ3JraHc5ZkN5Z2RvSlRXZHZpWU…
GLMD Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE4ySGxOdjRUdlNvQWlNdmxSVHlwaU15ckh6VFJjQnYyRGkzZ3hJYzE4X2dhb2dnd3RpbkRlMExRMFludnFpYzhnLVp5WEFlOEdPYmlXazZrZUdPZTNhQXc?oc=5" target="_blank">GLMD Should I Buy</a> <font c…
GLMD — Frequently Asked Questions
What is the current share price of GLMD?
As of 2026-08-05 17:25 PDT, GLMD trades at $0.58 on NASDAQ/NYSE. Its 52-week range is $0.47 to $1.63.
What is the market capitalisation of GLMD?
GLMD has a market capitalisation of $3.82M on NASDAQ/NYSE.
What is the P/E ratio of GLMD?
GLMD trades at a trailing price-to-earnings (P/E) ratio of -0.24. Its price-to-book (P/B) ratio is 0.24.
What is the return on equity (ROE) of GLMD?
GLMD has a return on equity (ROE) of -65.32%. Its return on capital employed (ROCE) is -53.92%.
Is GLMD a good stock to buy?
This page provides a data-driven analysis of GLMD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.